정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1101 | Recruiting | LIBERATE Trial in COVID-19 | SARS-CoV Infection | Drug: Ibuprofen | Phase 4 | King's College London, Guy's & St Thomas NHS Foundation Trust | OTHER | 230 | All | 18 Years | Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom |
| 1100 | Recruiting | Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home | Covid19 | Biological: Ligilactobacillus salivarius MP101 | Not Applicable | Universidad Complutense de Madrid | OTHER | 25 | All | 74 Years ~ 98 Years | Centro Para Mayores Santa Isabel, S.L., Moralzarzal, Madrid, Spain |
| 1099 | Completed | Lipid Emulsion Infusion and COVID-19 Patients | Covid19 | Drug: SMOFlipid Other: 0.9% saline |
Phase 3 | Assiut University | OTHER | 74 | All | 18 Years | Assiut university hospital, Assiut, Assuit, Egypt |
| 1098 | Completed | Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers | Covid19 | Drug: inhaled hydroxychloroquine | Phase 1 | University Medical Center Groningen | OTHER | 12 | All | 18 Years ~ 65 Years | University Medical Center Groningen, Groningen, Netherlands |
| 1097 | Completed | London's Exogenous Surfactant Study for COVID19 | COVID-19 | Drug: Bovine Lipid Extract Surfactant | Phase 2 | Lawson Health Research Institute, London Health Sciences Centre | OTHER | 20 | All | 18 Years | London Health Sciences Centre - University Hospital, London, Ontario, Canada Victoria Hospital, London, Ontario, Canada |
| 1096 | Recruiting | Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19. | COVID-19 | Biological: SCB-2019 | Phase 1 | Clover Biopharmaceuticals AUS Pty Ltd | INDUSTRY | 150 | All | 18 Years ~ 75 Years | Linear Clinical Research, Nedlands, Territory Western Australia, Australia |
| 1095 | Completed | Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | Novel Coronavirus Infection | Drug: Lopinavir/ritonavir Drug: Ribavirin Drug: Interferon Beta-1B |
Phase 2 | The University of Hong Kong, Hospital Authority, Hong Kong | OTHER | 127 | All | 18 Years | University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong |